Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Prices $35M Public Stock Offering

NEW YORK (GenomeWeb) – Liquid biopsy test developer OncoCyte announced today its public offering of about 9.3 million shares of its common stock at $3.75 per share for gross proceeds of approximately $35 million.

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.4 million shares of common stock at the public offering price to cover any overallotments.

Piper Jaffray is acting as the sole book-running manager and Janney Montgomery Scott is acting as the comanager for the offering, which should close on or about February 12.   

OncoCyte intends to use the proceeds to support commercialization of it DetermaVu test, a blood-based assay to aid in differentiating benign from cancerous lung nodules when they are discovered either in lung cancer screening programs or incidentally by imaging for an unrelated condition.

Money raised will help the company complete clinical studies to support reimbursement and adoption of the test, and to initiate future product development.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.